Disease diagnostics technology developer Mammoth Biosciences is valued at over $1bn following funding rounds backed by investors including Amazon.
US-based disease diagnostics technology developer Mammoth Biosciences has raised $195m across its series C and D funding rounds from investors including e-commerce group Amazon, it disclosed yesterday.
The company, which is now valued at over $1bn, received $150m of series D funding in a round led by investment firm Redmile Group and backed by Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX and Plum Alley Investments.
Redmile Group had also joined Foresite Capital to co-lead…
